Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0I3WC
|
|||
| Former ID |
DIB000358
|
|||
| Drug Name |
RO-4929097
|
|||
| Synonyms |
RO4929097; 847925-91-1; Ro 4929097; UNII-KK8645V7LE; KK8645V7LE; RG-4733; N1-[(7S)-6,7-dihydro-6-oxo-5H-dibenz[b,d]azepin-7-yl]-2,2-dimethyl-N3-(2,2,3,3,3-pentafluoropropyl)propanediamide; n1-((7s)-6,7-dihydro-6-oxo-5h-dibenz(b,d)azepin-7-yl)-2,2-dimethyl-n3-(2,2,3,3,3-pentafluoropropyl)propanediamide; OJPLJFIFUQPSJR-INIZCTEOSA-N; cc-19; MLS006011071; SCHEMBL1376366; GTPL7338; CHEBI:86474; DTXSID20233833; C22H20F5N3O3; MolPort-016-633-243; BCPP000088; EX-A1750; ZINC43208642; ABP000966; s1575; AKOS027250816
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Breast cancer [ICD-11: 2C60-2C65] | Phase 2 | [1], [2] | |
| Company |
Roche
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C22H20F5N3O3
|
|||
| Canonical SMILES |
CC(C)(C(=O)NCC(C(F)(F)F)(F)F)C(=O)NC1C2=CC=CC=C2C3=CC=CC=C3NC1=O
|
|||
| InChI |
1S/C22H20F5N3O3/c1-20(2,18(32)28-11-21(23,24)22(25,26)27)19(33)30-16-14-9-4-3-7-12(14)13-8-5-6-10-15(13)29-17(16)31/h3-10,16H,11H2,1-2H3,(H,28,32)(H,29,31)(H,30,33)/t16-/m0/s1
|
|||
| InChIKey |
OJPLJFIFUQPSJR-INIZCTEOSA-N
|
|||
| CAS Number |
CAS 847925-91-1
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID |
104253224, 121143589, 124757349, 125164153, 135323407, 135727396, 136348257, 136349997, 136367552, 136367801, 137276006, 137710929, 152258320, 160647159, 162011370, 162037674, 162202738, 163907988, 174006710, 174530815, 178103910, 184819500, 198939144, 223705127, 223929894, 227593850, 243630441, 252110184, 252162573, 252216215
|
|||
| ChEBI ID |
CHEBI:86474
|
|||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7338). | |||
| REF 2 | Phase I study of RO4929097, a gamma secretase inhibitor of Notch signaling, in patients with refractory metastatic or locally advanced solid tumors. J Clin Oncol. 2012 Jul 1;30(19):2348-53. | |||
| REF 3 | Phase 2 study of RO4929097, a gamma-secretase inhibitor, in metastatic melanoma: SWOG 0933.Cancer.2015 Feb 1;121(3):432-440. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.